# Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

> **NCT02132884** · NA · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Malignant Pericardial Effusion
- Malignant Pleural Effusion
- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **OTHER:** cytology specimen collection procedure
- **PROCEDURE:** therapeutic procedure
- **DRUG:** targeted therapy
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02132884
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Feasibility
- **Last updated:** 2019-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02132884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02132884, "Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02132884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*